Non-Cochrane · aetiology · PM42353214
Dysbiosis and Immune Crosstalk in Experimental Diabetic Periodontitis: A Systemic Review and Meta-Analysis of Preclinical Murine Studies.
Harrandah Amani M · International journal of molecular sciences · 2026 · PubMed · doi:10.3390/ijms27125499
Findings
Population Murine models of diabetic periodontitis (db/db, NOD, germ-free recipients, diabetic mice with salivary microbiome transplant)
4 findings
| Exposure to diabetic/dysbiotic oral microbiota or diabetic condition | Normoglycemic/eubiotic controls (healthy microbiota, healthy-saliva microbiome, or probiotic-treated) | Immune activation and periodontal inflammation (combined) Preclinical laboratory animal studies · Sensitivity analysis: reported SE converted to SD (SD = SE x sqrt(n)) | SMD (Hedges' g) 1.61 [1.13, 2.09] GRADE not reported 4 studies |
| Exposure to diabetic/dysbiotic oral microbiota or diabetic condition | Normoglycemic/eubiotic controls (healthy microbiota, healthy-saliva microbiome, or probiotic-treated) | Periodontal inflammation and bone destruction Preclinical laboratory animal studies · Domain subgroup: periodontal inflammation | SMD (Hedges' g) 3.37 [2.21, 4.53] GRADE not reported Studies not reported |
| Exposure to diabetic/dysbiotic oral microbiota or diabetic condition | Normoglycemic/eubiotic controls (healthy microbiota, healthy-saliva microbiome, or probiotic-treated) | Immune activation and periodontal inflammation (combined) Preclinical laboratory animal studies | SMD (Hedges' g) 3.73 [2.96, 4.51] GRADE not reported 4 studies |
| Exposure to diabetic/dysbiotic oral microbiota or diabetic condition | Normoglycemic/eubiotic controls (healthy microbiota, healthy-saliva microbiome, or probiotic-treated) | Immune activation (Th17/IL-17 axis) Preclinical laboratory animal studies · Domain subgroup: immune activation | SMD (Hedges' g) 4.03 [2.98, 5.07] GRADE not reported Studies not reported |
Included primary studies 3
Open in Studies| Study | Year | Also included by | Outcomes it informs here | Trial data |
|---|---|---|---|---|
| Dolpady 2016 Oral Probiotic VSL#3 Prevents Autoimmune Diabetes by Modulating Microbiota and Promoting Indoleamine 2,3-Dioxygenase-Enriched Tolerogenic… PMID:26779542 | 2016 | this review only | Immune activation and periodontal inflammation (combined) | not extracted yet |
| He 2022 Human periodontitis-associated salivary microbiome affects the immune response of diabetic mice. PMID:35958276 | 2022 | this review only | Immune activation and periodontal inflammation (combined) | not extracted yet |
| Xiao 2017 Diabetes Enhances IL-17 Expression and Alters the Oral Microbiome to Increase Its Pathogenicity. PMID:28704648 | 2017 | this review only | Immune activation and periodontal inflammation (combined) | not extracted yet |
Review question
| Element | Planned (methods) | Found (results) |
|---|---|---|
| Population | Human patients with type 1 or type 2 diabetes and periodontal disease, or murine models mimicking these conditions | Murine models (db/db, germ-free recipients, NOD, diabetic mice with human salivary microbiome transplantation); 4 studies, 8 comparisons in meta-analysis |
| Intervention | Exposure: oral/salivary microbiome and its systemic or localized immunological effects | Diabetic/dysbiotic oral microbiota exposure |
| Comparison | Not specified | Normoglycemic/eubiotic microbiota or control mice |
| Outcomes | Microbial taxonomic shifts and local/systemic immune markers (IL-17, TNF-alpha, IL-1beta, Th17 frequency, Treg differentiation, alveolar bone loss) | IL-17A mRNA, Th17 cell frequency, osteoclasts, TNF-alpha, IL-1beta (Hedges g) |
| Study designs | In vivo animal models and human observational, cross-sectional or randomized studies | In vivo preclinical murine studies |
| Timing | Not specified | Not specified |